Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Pancreatic cancer exhibits high mortality with a 5-year survival rate of 5-10%.
• Immunotherapy, specifically anti-programmed cell death protein 1/ligand 1 (anti-PD-(L)1) antibodies, is successful in many cancers.
• The immune-suppressive tumor microenvironment limits anti-PD-(L)1 efficacy in pancreatic cancer.

Purpose of the Study:

• To review current combination strategies involving anti-PD-(L)1 for pancreatic cancer.
• To highlight potential adverse effects of combined therapies.
• To suggest future directions for optimizing anti-PD-(L)1 combination treatments.

Main Methods:

• Review of preclinical and clinical investigations combining anti-PD-(L)1 with chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
• Analysis of current literature on anti-PD-(L)1 combination strategies in pancreatic cancer.
• Identification of potential adverse effects and future optimization approaches.

Main Results:

• Various combination therapies with anti-PD-(L)1 have been explored for pancreatic cancer.
• Challenges remain due to the immunosuppressive tumor microenvironment.
• Potential for adverse effects necessitates careful consideration of cumulative treatments.

Conclusions:

• Optimizing anti-PD-(L)1 combination therapy is crucial for improving pancreatic cancer outcomes.
• Future strategies may involve targeting post-translational modifications of PD-(L)1.
• Enhancing treatment precision is key to maximizing therapeutic benefits and minimizing toxicity.